BioCentury
ARTICLE | Clinical News

4SC-203: Phase I data

January 17, 2011 8:00 AM UTC

A double-blind, placebo-controlled, German Phase I trial in 60 healthy male volunteers ages 20-46 showed that single-ascending doses of 0.041-2.5 mg/kg IV 4SC-203 were well tolerated with no dose-depe...